Payment overview · 2025
General Payments
$1,915.93
119 reported records · 27 companies
Healthcare provider profile · identity verified
Michael App, MD
Allopathic & Osteopathic Physicians|Pediatrics · GRAND RAPIDS, MI · NPI 1467490953
Verified facts
What the public records show
CMS Open Payments records show Michael App, MD received $1,915.93 in general payments during 2025 across 119 reported records.
PFIZER INC. accounted for 13.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 48 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Eliquis, Farxiga, Mounjaro, Ozempic, Paxlovid, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 3673 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HAVRIX as an associated drug or biological on 10 records involving 10 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Havrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 2921 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VAQTA as an associated drug or biological on 1592 records involving 1446 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Vaqta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 598 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $256.27 | 13.4% | 13 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $225.78 | 11.8% | 25 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $195.20 | 10.2% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $172.90 | 9.0% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $143.78 | 7.5% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $141.96 | 7.4% | 10 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $84.41 | 4.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $83.71 | 4.4% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $82.02 | 4.3% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $50.37 | 2.6% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $44.80 | 2.3% | 2 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $43.09 | 2.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.37 | 1.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.98 | 1.9% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $33.93 | 1.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $33.16 | 1.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.43 | 1.6% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $29.08 | 1.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $28.62 | 1.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.25 | 1.2% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $22.51 | 1.2% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $21.86 | 1.1% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $21.50 | 1.1% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $20.45 | 1.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.07 | 1.1% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $18.52 | 1.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.91 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,855.93 | 118 |
| Education | $60.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $225.78 | 25 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $158.45 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $150.65 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $143.87 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $96.18 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $93.41 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $88.46 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $83.71 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $76.72 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $75.13 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $66.22 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $52.08 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $50.37 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $49.33 | 2 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $46.06 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $44.80 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.55 | 2 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $43.09 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $42.68 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $42.68 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $40.26 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.37 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $35.98 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $35.45 | 2 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $33.16 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $33.16 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $33.16 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $32.69 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $31.60 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $31.46 | 3 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $29.08 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $28.62 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.48 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 598 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 3673 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 90 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 12 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 2921 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
90 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
3673 | 3662 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | HAVRIX open payments reported associated product |
CMS Open Payments — General Payments 10 supporting records · 10 recipient NPIs · example record 1190350374 |
Havrix · 2024 Exact normalized brand match · 1 Part D row |
181 | 179 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
2921 | 2284 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VAQTA open payments reported associated product |
CMS Open Payments — General Payments 1592 supporting records · 1446 recipient NPIs · example record 1237992242 |
Vaqta · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
598 | 595 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
90 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 3673 | 3662 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 2921 | 2284 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 1543 | 1540 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 598 | 595 |
| Atorvastatin Calcium | Atorvastatin Calcium | 382 | 118 |
| Twinrix | Hepatitis A And B Vaccine/Pf | 316 | 212 |
| Levothyroxine Sodium | Levothyroxine Sodium | 241 | 67 |
| Havrix | Hepatitis A Virus Vaccine/Pf | 181 | 179 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 48 |
| Omeprazole | Omeprazole | 169 | 55 |
| Lisinopril | Lisinopril | 147 | 53 |
| Losartan Potassium | Losartan Potassium | 136 | 47 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 130 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 123 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 30 |
| Tramadol Hcl | Tramadol Hcl | 93 | 16 |
| Eliquis | Apixaban | 90 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 26 |
| Gabapentin | Gabapentin | 83 | 20 |
| Alprazolam | Alprazolam | 77 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 22 |
| Metformin Hcl | Metformin Hcl | 71 | 27 |
| Simvastatin | Simvastatin | 64 | 21 |
| Sertraline Hcl | Sertraline Hcl | 63 | 21 |
| Metformin Hcl Er | Metformin Hcl | 59 | 13 |
| Furosemide | Furosemide | 57 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 57 | 25 |
| Bupropion Xl | Bupropion Hcl | 55 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 17 |
| Mounjaro | Tirzepatide | 54 | suppressed |
| Meloxicam | Meloxicam | 53 | 18 |
| Trazodone Hcl | Trazodone Hcl | 52 | 20 |
| Prednisone | Prednisone | 49 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | suppressed |
| Carvedilol | Carvedilol | 46 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 14 |
| Potassium Chloride | Potassium Chloride | 40 | 15 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Dutasteride | Dutasteride | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 15 |
| Atenolol | Atenolol | 34 | 13 |
| Montelukast Sodium | Montelukast Sodium | 34 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | 11 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | 11 |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 25 |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 13 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Vaqta | Hepatitis A Virus Vaccine/Pf | 27 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Azithromycin | Azithromycin | 24 | 17 |
| Celecoxib | Celecoxib | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 17 |
| Temazepam | Temazepam | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Tenivac | Tetanus-Diphtheria Toxoids/Pf | 21 | 21 |
| Testosterone | Testosterone | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| M-M-R Ii Vaccine | Measles,mumps,rubella Vacc/Pf | 12 | 12 |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,915.93 · 119 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AJOVY, AREXVY, AUSTEDO XR, Auvelity, BREZTRI, CAMZYOS, CAPLYTA, COMIRNATY, CT THROMBECTOMY SYSTEM KIT, Cologuard Collection Kit, Doc Band, ELIQUIS, ENFLONSIA, EPIDIOLEX, FARXIGA, FLOWTRIEVER CATHETER, S, INJECTAFER, INSPIRE, JARDIANCE, Jornay PM, KISUNLA, Kerendia, Korlym, MOUNJARO, NEFFY, NURTEC ODT, OPSUMIT, Ozempic, PAXLOVID, PENBRAYA, PREVNAR 20, PROQUAD, QULIPTA, REXULTI, Rybelsus, SHINGRIX, Senza, TRELEGY ELLIPTA, TRUMENBA, UBRELVY, VAXELIS, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error